This week, we’re reading about Novo’s rebrand, CVS’ efforts to take over the markets Walgreens is exiting, and the prospects of the GLP-1 Bridge program, among many other topics.
- Endpoints News: HHS official Klomp spars with Warren over drug pricing contracts
- Endpoints News: FDA suggests regulatory flexibility for assessing psychedelics
- Endpoints News: Seeking a fresh start, Novo drops the 'Nordisk'
- Chain Drug Review: AAM: Generics and biosimilars saved U.S. health system $496 billion in 2025
- Axios: Biosimilars stuck in a rut
- Becker’s Hospital Review: Medicare’s GLP-1 program is ‘far exceeding’ expectations, but a plateau could be coming
- The Street: Will Walgreens store closures benefit CVS in key markets?
- USA Today: Injectable drugs sold nationwide recalled. See affected products
- WOSU: ‘A financial lifeline’: Rural pharmacists hope federal funds can bridge healthcare gaps
- KARK: Group of independent Arkansas pharmacies sue Pharmacy Benefit Manager, allege underpayment
- KWQC: Community Health Care opens comprehensive Muscatine clinic, will add pharmacy soon
- Greensboro Times: 5th District candidates stress rural healthcare investment, Medicaid access
- 13ABC: Pharmacies are expanding healthcare access for Ohio’s rural communities
- The Vermont Journal: North Star Pharmacies grand opening celebrations
- CT Mirror: CT insurance department approves rate hikes for 2027 health plans
- Gila Valley Central: Ribbon-cutting celebrates opening of The Pharmacy at Mt. Graham
NCPA
